Drug reference

Tafluprost

Vasodilator · Antiglaucoma Agent

VasodilatorAntiglaucoma Agent

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies.

FDA category + note

Mechanism

Tafluprost is a prostaglandin analogue. It acts primarily by increasing the outflow of aqueous humor from the eye, thereby reducing intra-ocular pressure.

Indications

Raised intra-ocular pressure in open-angle glaucomaOcular hypertensionglaucoma

Dosing

Adult: Apply once daily, to be administered preferably in the evening
Renal adjustment: Use with caution (no information available)
Hepatic adjustment: Manufacturer advises caution (no information available)

Contraindications

Angle-closure glaucoma (no experience of use)
Aphakia
Asthma
Congenital glaucoma (no experience of use)
Contact lens wearers
Inflammatory ocular conditions (no experience of use)
Narrow-angle glaucoma (no experience of use)
Neovascular glaucoma (no experience of use)
Pseudophakia with torn posterior lens capsule or anterior chamber lenses
Risk factors for cystoid macular oedema
Risk factors for iritis
Risk factors for uveitis

Side effects

Common

Dry eyeEye discolourationEye discomfortEye disordersEye inflammationHeadacheVision disordersHypertrichosislash growthallergic conjunctival hyperemiapermanent increase in iris pigmentationorbital fat atrophy

Serious